Artelo Biosciences (ARTL) Competitors

Artelo Biosciences logo
$1.35 -0.10 (-6.97%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.37 +0.02 (+1.26%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARTL vs. NCNA, SILO, MDCX, RDHL, and GRI

Should you buy Artelo Biosciences stock or one of its competitors? Artelo Biosciences's main competitors and comparable companies include NuCana (NCNA), Silo Pharma (SILO), Medicus Pharma (MDCX), Redhill Biopharma (RDHL), and GRI Bio (GRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Artelo Biosciences compare to NuCana?

Artelo Biosciences (NASDAQ:ARTL) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NuCana is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$47.20N/A
NuCanaN/AN/A-$38.71M-$4.18N/A

In the previous week, NuCana had 3 more articles in the media than Artelo Biosciences. MarketBeat recorded 3 mentions for NuCana and 0 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company Overall Sentiment
Artelo Biosciences Neutral
NuCana Neutral

Artelo Biosciences has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, NuCana has a beta of 2.39, meaning that its stock price is 139% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NuCana's return on equity of -51.18% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -272.21% -159.13%
NuCana N/A -51.18%-41.16%

Summary

NuCana beats Artelo Biosciences on 7 of the 9 factors compared between the two stocks.

How does Artelo Biosciences compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Silo Pharma has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 3.6% of Silo Pharma shares are held by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Silo Pharma has higher revenue and earnings than Artelo Biosciences. Silo Pharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silo Pharma$70K52.77-$4.23M-$2.77N/A
Artelo BiosciencesN/AN/A-$12.88M-$47.20N/A

In the previous week, Silo Pharma's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company Overall Sentiment
Silo Pharma Neutral
Artelo Biosciences Neutral

Artelo Biosciences has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -58.79% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Silo Pharma-6,726.39% -58.79% -50.68%
Artelo Biosciences N/A -272.21%-159.13%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silo Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Artelo Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Silo Pharma beats Artelo Biosciences on 8 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to Medicus Pharma?

Artelo Biosciences (NASDAQ:ARTL) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Artelo Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Artelo Biosciences' return on equity of -272.21% beat Medicus Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -272.21% -159.13%
Medicus Pharma N/A -3,137.84%-296.44%

Artelo Biosciences is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$47.20N/A
Medicus PharmaN/AN/A-$35.46M-$78.64N/A

In the previous week, Medicus Pharma had 9 more articles in the media than Artelo Biosciences. MarketBeat recorded 9 mentions for Medicus Pharma and 0 mentions for Artelo Biosciences. Medicus Pharma's average media sentiment score of 0.13 beat Artelo Biosciences' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Artelo Biosciences Neutral
Medicus Pharma Neutral

Medicus Pharma has a consensus price target of $450.00, indicating a potential upside of 39,547.58%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Artelo Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Medicus Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

0.9% of Artelo Biosciences shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 14.4% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Medicus Pharma beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Artelo Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Redhill Biopharma's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Redhill BiopharmaN/A N/A N/A
Artelo Biosciences N/A -272.21%-159.13%

Redhill Biopharma has higher revenue and earnings than Artelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redhill Biopharma$290K8.61-$430KN/AN/A
Artelo BiosciencesN/AN/A-$12.88M-$47.20N/A

Redhill Biopharma has a beta of 4.93, meaning that its stock price is 393% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Redhill Biopharma had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 1 mentions for Redhill Biopharma and 0 mentions for Artelo Biosciences. Redhill Biopharma's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company Overall Sentiment
Redhill Biopharma Neutral
Artelo Biosciences Neutral

Summary

Redhill Biopharma beats Artelo Biosciences on 8 of the 8 factors compared between the two stocks.

How does Artelo Biosciences compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

GRI Bio is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$3.21N/A
Artelo BiosciencesN/AN/A-$12.88M-$47.20N/A

GRI Bio's return on equity of -87.61% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -87.61% -75.89%
Artelo Biosciences N/A -272.21%-159.13%

GRI Bio currently has a consensus price target of $21.00, indicating a potential upside of 1,775.00%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts clearly believe GRI Bio is more favorable than Artelo Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Artelo Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 0.6% of GRI Bio shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, GRI Bio had 5 more articles in the media than Artelo Biosciences. MarketBeat recorded 5 mentions for GRI Bio and 0 mentions for Artelo Biosciences. GRI Bio's average media sentiment score of 0.33 beat Artelo Biosciences' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company Overall Sentiment
GRI Bio Neutral
Artelo Biosciences Neutral

GRI Bio has a beta of -1.13, meaning that its share price is 213% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

GRI Bio beats Artelo Biosciences on 10 of the 13 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTL vs. The Competition

MetricArtelo BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.30M$13.12B$7.44B$10.86B
Dividend YieldN/A2.62%2.51%4.69%
P/E Ratio-0.0327.8232.5628.72
Price / SalesN/A7.078.005.34
Price / CashN/A15.2220.2520.77
Price / Book0.205.164.343.51
Net Income-$12.88M$2.86B$3.51B$394.12M
7 Day Performance-34.83%-7.27%-8.07%-8.97%
1 Month Performance-47.10%-9.60%-10.29%-11.61%
1 Year Performance-97.01%-9.28%-4.70%-11.21%

Artelo Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTL
Artelo Biosciences
0.4006 of 5 stars
$1.35
-7.0%
N/A-97.0%$1.30MN/AN/A7
NCNA
NuCana
0.4247 of 5 stars
$0.88
+2.0%
N/A-78.6%$3.59MN/AN/A11
SILO
Silo Pharma
0.5956 of 5 stars
$1.71
+8.6%
N/A-70.8%$3.40M$70KN/A3
MDCX
Medicus Pharma
2.1611 of 5 stars
$1.52
-10.1%
$450.00
+29,505.3%
-98.9%$3.25MN/AN/A16
RDHL
Redhill Biopharma
0.5038 of 5 stars
$0.35
-2.9%
N/A-73.7%$3.20M$290KN/A210

Related Companies and Tools


This page (NASDAQ:ARTL) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners